LMX.F - Luminex Corporation

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Luminex Corporation

12212 Technology Boulevard
Austin, TX 78727
United States
512 219 8020
http://www.luminexcorp.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees1,257

Key Executives

NameTitlePayExercisedYear Born
Mr. Nachum ShamirCEO, Pres & Director1.36MN/A1954
Mr. Harriss T. CurrieCFO, Sr. VP of Fin. & Treasurer630.63kN/A1962
Mr. Richard W. Rew IISr. VP, Gen. Counsel & Corp. Sec.539.33kN/A1968
Mr. Todd C. BennettSr. VP of Global Sales & Customer Operations500.04kN/A1970
Mr. Randall J. MyersSr. VP of Global Manufacturing & Quality484.9kN/A1962
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Corporate Governance

Luminex Corporation’s ISS Governance QualityScore as of December 7, 2019 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.